The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
Open accessAbstract
Background Intravenous ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide. The Implicit Association Test (IAT), a performance-based measure of association between concepts, may have utility in suicide assessment.Methods Twenty-six patients with treatment-resistant depression were assessed using the suicidality item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI) 2 hours before and 24 hours following a single subanesthetic dose of intravenous ketamine. Ten patients also completed IATs assessing implicit suicidal associations at comparable time points. In a second study, nine patients received thrice-weekly ketamine infusions over a 12-day period.Results Twenty-four hours after a single infusion, MADRS-SI scores were reduced on average by 2.08 points on a 0 to 6 scale (p < .001; d = 1.37), and 81% of patients received a rating of 0 or 1 postinfusion. Implicit suicidal associations were also reduced following ketamine (p = .003; d = 1.36), with reductions correlated across implicit and explicit measures. MADRS-SI reductions were sustained for 12 days by repeated-dose ketamine (p < .001; d = 2.42).Conclusions These preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine's half-life in the body is ;2 h (Autry et al., 2011), yet a single low-dose treatment elicits sustained (.1 week) antidepressant effects in patients (Berman et al., 2000;Zarate et al., 2006;Price et al., 2009), strongly suggesting it induces neuroplasticity (Duman, 2018).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Price et al., 2009
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ketamine rapidly induces flexibility in implicit representations of self on the Implicit Association Test 134,135 , and these shifts correlated with self-reported symptom improvements 110 , suggesting that ketamine can immediately impact the structure of implicit mental representations relevant to one's concept of self, a core form of cognitive bias in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [135]
In the citing paper
“Critically, several versions of the IAT have also been incorporated into clinical ketamine trials, which found that the “escape” version of the IAT (instead of “death,” the participant links the self with “escape” or “stay”) was associated with reductions in SI (57, 58).”
From New methods for assessing rapid changes in suicide risk (2021) · cites this paper as [57]
In the citing paper
“Administration of glutamate receptor antagonists, such as the NMDA antagonist, ketamine, have potent antidepressant effects especially in treatment resistant depressed patients”
From Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications (2013) · cites this paper as Price et al., 2009
In the citing paper
“Recent studies report that ketamine also reduces suicide ideation, a major advance over typical antidepressants with low efficacy and delayed onset of action151,152.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [152]
In the citing paper
“Ketamine has been also shown to induce a rapid amelioration of suicidal ideation in major depressed patients 23, 24”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Measuring individual differences in implicit cognition: the implicit association test
Greenwald, A. G., McGhee, D. E., & Schwartz, J. L. K. (1998) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.74.6.1464 · Cited by 9,210
Understanding and using the Implicit Association Test: I. An improved scoring algorithm.
Greenwald, A. G., Nosek, B. A., & Banaji, M. R. (2003) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.85.2.197 · Cited by 5,815
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationUnderstanding and using the Implicit Association Test: III. Meta-analysis of predictive validity.
Greenwald, A. G., Poehlman, T. A., Uhlmann, E. L., & Banaji, M. R. (2009) · Journal of Personality and Social Psychology · doi:10.1037/a0015575 · Cited by 3,257
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Understanding and Using the Implicit Association Test: II. Method Variables and Construct Validity
Nosek, B. A., Greenwald, A. G., & Banaji, M. R. (2004) · Personality and Social Psychology Bulletin · doi:10.1177/0146167204271418 · Cited by 1,216
Cited by
Sorted by citations
Items 301–400 of 601
Ketamine for Treatment-Resistant Depression
Zarate Jr, C. A., & Mathew, S. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0 · Cited by 34
Self-citationAgmatine as a novel candidate for rapid-onset antidepressant response
Valverde, A. P., Camargo, A., & Rodrigues, A. L. S. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i11.981 · Cited by 31
Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches
Jurdi, R. K. A., Swann, A. C., & Mathew, S. J. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0614-9 · Cited by 31
Self-citationRay-Griffith, S. L., Eads, L. A., Han, X., Golden, K., & Stowe, Z. N. (2017) · Journal of Ect · doi:10.1097/yct.0000000000000413 · Cited by 30
Individuals with current suicidal ideation demonstrate implicit “fearlessness of death”
Hussey, I., Barnes-Holmes, D., & Booth, R. (2016) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2015.11.003 · Cited by 29
Yang, C., Li, W.-Y., Yu, H.-Y., Gao, Z.-Q., Liu, X.-L., Zhou, Z.-Q., & Yang, J.-J. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/175619 · Cited by 29
Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist properties
Kang, H., Park, P., Bortolotto, Z. A., Brandt, S. D., Colestock, T., Wallach, J. V., Collingridge, G. L., & Lodge, D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.004 · Cited by 29
Anorexia nervosa, zinc deficiency and the glutamate system: The ketamine option
Hermens, D. F., Simcock, G. P., Dutton, M., Bouças, A. P., Can, A., Lilley, C. J., & Lagopoulos, J. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109921 · Cited by 30
Poleszak, E., Stasiuk, W., Szopa, A., Wyska, E., Serefko, A., Oniszczuk, A., Wośko, S., Świąder, K., & Właź, P. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9810-5 · Cited by 30
Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants
Chaki, S., & Fukumoto, K. (2015) · Pharmaceuticals · doi:10.3390/ph8030590 · Cited by 29
Machado‐Vieira, R., & Zarate, C. A. (2011) · Depression and Anxiety · doi:10.1002/da.20800 · Cited by 29
Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression
Henter, I. D., SOUSA, R. T. D., Gold, P. W., Brunoni, A. R., Zarate, C. A., & Machado‐Vieira, R. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1253472 · Cited by 29
Canuso, C. M., Singh, J. B., Fedgchin, M. M., Alphs, L. D., Lane, R., Lim, P., Pinter, C., Hough, D. W., Sanacora, G., Manji, H. K., et al. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.17105 · Cited by 32
Novel Targets for Fast Antidepressant Responses: Possible Role of Endogenous Neuromodulators
Camargo, A., & Rodrigues, A. L. S. (2019) · Chronic Stress · doi:10.1177/2470547019858083 · Cited by 28
Zhu, J., Hawkins, E., Phillips, K. F., & Deshpande, L. S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17134710 · Cited by 28
Camargo, A., Dalmagro, A. P., de Souza, M. M., Zeni, A. L. B., & Rodrigues, A. L. S. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113459 · Cited by 29
Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression
Borsellino, P., Krider, R. I., Chea, D., Grinnell, R., & Vida, T. A. (2023) · Pharmaceuticals · doi:10.3390/ph16050742 · Cited by 29
Bryan, C. J. (2018) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12447 · Cited by 26
DNA methylation in stress and depression: from biomarker to therapeutics
Sales, A. J., Guimarães, F. S., & Joca, S. R. L. (2021) · Acta Neuropsychiatrica · doi:10.1017/neu.2021.18 · Cited by 29
Effects of somatic treatments on suicidal ideation and completed suicides
Hawkins, E. M., Coryell, W. H., Leung, S., Parikh, S. V., Weston, C. L., Nestadt, P. S., Nürnberger, J. I., Kaplin, A. I., Kumar, A., Farooqui, A. A., et al. (2021) · Brain and Behavior · doi:10.1002/brb3.2381 · Cited by 28
Prados-Pardo, Á., Martín-González, E., Mora, S., Merchán, A., Flores, P., & Moreno, M. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00100 · Cited by 25
Sex differences in brain gene expression among suicide completers
Cabrera‐Mendoza, B., Fresno, C., Monroy‐Jaramillo, N., Fries, G. R., Walss‐Bass, C., Glahn, D. C., Ostrosky‐Wegman, P., Mendoza-Morales, R., García‐Dolores, F., Díaz‐Otañez, C. E., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.167 · Cited by 25
The Role of Beta-Adrenergic Receptors in Depression and Resilience
Zhang, H., Cui, M., Cao, J., & Han, M. (2022) · Biomedicines · doi:10.3390/biomedicines10102378 · Cited by 26
The Effect of Intravenous Ketamine in Suicidal Ideation of Emergency Department Patients.
Kashani, P., Yousefian, S., Amini, A., Heidari, K., Younesian, S., & Hatamabadi, H. (2014) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v2i1.20 · Cited by 26
Lu, R. (2012) · InTech eBooks · doi:10.5772/2268 · Cited by 24
Hara, H., Suzuki, A., Kunugi, A., Tajima, Y., Yamada, R. X., & Kimura, H. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173289 · Cited by 24
Pradhan, B., Parikh, T., Makani, R. D., & Sahoo, M. (2015) · Depression Research and Treatment · doi:10.1155/2015/842817 · Cited by 28
Implicit Measures of Suicide Risk in a Military Sample
Chiurliza, B., Hagan, C. R., Rogers, M. L., Podlogar, M. C., Hom, M. A., Stanley, I. H., & Joiner, T. E. (2016) · Assessment · doi:10.1177/1073191116676363 · Cited by 24
Ren, L. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110910 · Cited by 23
Veen, C., Jacobs, G. E., Philippens, I. H. C. H. M., & Vermetten, E. H. G. J. M. (2018) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_34 · Cited by 22
Chen, Q., Dong, J., Luo, J., Ren, L., Min, S., Hao, X., Luo, Q., Chen, J., & Li, X. (2020) · Journal of Ect · doi:10.1097/yct.0000000000000636 · Cited by 22
Ludwig, V. M., Sauer, C., Young, A. H., Rucker, J., Bauer, M., Findeis, H., & Ritter, P. S. (2021) · CNS Drugs · doi:10.1007/s40263-021-00837-6 · Cited by 21
Nikayin, S., & Sanacora, G. (2021) · CNS Drugs · doi:10.1007/s40263-021-00851-8 · Cited by 24
Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior
Mallick, F., & McCullumsmith, C. B. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0680-7 · Cited by 22
Brain Gene Expression Pattern of Subjects with Completed Suicide and Comorbid Substance Use Disorder
Cabrera‐Mendoza, B., Monroy‐Jaramillo, N., Fries, G. R., Mendoza-Morales, R., García‐Dolores, F., Mendoza-Larios, A., Díaz‐Otañez, C. E., Walss‐Bass, C., Glahn, D. C., Ostrosky‐Wegman, P., et al. (2018) · Complex Psychiatry · doi:10.1159/000493940 · Cited by 22
Ketamine in the Treatment of Depressive Episodes
Ritter, P. S., Findeis, H., & Bauer, M. (2019) · Pharmacopsychiatry · doi:10.1055/a-0991-0582 · Cited by 26
Nicotine inhalation and suicide: clinical correlates and behavioral mechanisms
Swann, A. C., Graham, D. P., Wilkinson, A. V., & Kosten, T. R. (2021) · The American Journal on Addictions · doi:10.1111/ajad.13171 · Cited by 20
Subanesthetic ketamine decreases the incentive-motivational value of reward-related cues
Fitzpatrick, C. J., & Morrow, J. D. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116667709 · Cited by 21
Vasilescu, A.-N., Schweinfurth, N., Borgwardt, S., Gass, P., Lang, U. E., Inta, D., & Eckart, S. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s119004 · Cited by 21
A regulatory perspective on the evaluation of hallucinogen drugs for human use
Calderon, S. N., Hunt, J., & Klein, M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.028 · Cited by 23
Role of exercise on molecular mechanisms in the regulation of antidepressant effects
Lee, H., & Baek, S. (2017) · Journal of Exercise Rehabilitation · doi:10.12965/jer.1735188.594 · Cited by 21
General Anesthetics to Treat Major Depressive Disorder: Clinical Relevance and Underlying Mechanisms
Vutskits, L. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002594 · Cited by 20
Freudenberg, F., Marx, V., Mack, V., Layer, L. E., Klugmann, M., Seeburg, P. H., Sprengel, R., & Celikel, T. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.12.003 · Cited by 20
Lewis, V., Rodrigue, B., Arsenault, E., Zhang, M., Taghavi‐Abkuh, F., Silva, W. C. C., Myers, M., Matta‐Camacho, E., & Aguilar‐Valles, A. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15652 · Cited by 21
Ketamine for Treatment-Resistant Mood Disorders
Park, L. T., Falodun, T. B., & Zarate, C. A. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180030 · Cited by 22
Ketamine, benzoate, and sarcosine for treating depression
Cheng, Y., Lin, C., & Lane, H. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109351 · Cited by 20
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine
Wilkowska, A., & Cubała, W. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314605 · Cited by 19
Piroli, G. G., Reznikov, L. R., Grillo, C. A., Hagar, J. M., Fadel, J. R., & Reagan, L. P. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.005 · Cited by 19
Chan, L. F., Eu, C. L., Soh, S. Y., Maniam, T., Kadir, Z. S., Chong, B. T. W., Loo, J. L., Sharip, S., WONG, V. C. W., Loo, T. H., et al. (2018) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000316 · Cited by 19
Glutamine and New Pharmacological Targets to Treat Suicidal Ideation
Jiménez-Treviño, L., González-Blanco, L., Alvarez-Vázquez, C., Rodríguez-Revuelta, J., & Sáiz, P. A. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_168 · Cited by 19
Fraga, D. B., Camargo, A., Olescowicz, G., Padilha, D. A., Mina, F., Budni, J., Brocardo, P. S., & Rodrigues, A. L. S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00743-2 · Cited by 19
Myint, A.-M., & Halaris, A. E. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.913303 · Cited by 18
Heal, D. J., Gosden, J., Smith, S. L., & Atterwill, C. K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109375 · Cited by 19
Ketamine administration diminishes operant responding but does not impair conditioned fear
Travis, C. M. G., Altman, D. E., & Genovese, R. F. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.10.013 · Cited by 18
Camargo, A., Dalmagro, A. P., Wolin, I. A. V., Siteneski, A., Zeni, A. L. B., & Rodrigues, A. L. S. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110371 · Cited by 17
Paredes, D., Knippenberg, A. R., Bulin, S. E., Keppler, L. J., & Morilak, D. A. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100468 · Cited by 16
Individual and peer factors associated with ketamine use among adolescents in Taiwan
Lee, K., Yeh, Y.-C., Yang, P., Lin, H., Wang, P., Liu, T., & Yen, C. (2012) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0292-7 · Cited by 17
Bao, H., Ran, P., Zhu, M., Sun, L., Li, B., Hou, Y., Nie, J., Shan, L., Li, H., Zheng, S., et al. (2016) · Scientific Reports · doi:10.1038/srep28395 · Cited by 17
Hussey, I., Daly, T., & Barnes‐Holmes, D. (2015) · The Psychological Record · doi:10.1007/s40732-015-0142-3 · Cited by 17
Case Report: Efficacy and Tolerability of Ketamine in Opioid-Refractory Cancer Pain
Amin, P., Roeland, E. J., & Atayee, R. S. (2014) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2014.938881 · Cited by 17
Ketamine: A Review for Clinicians
Sanacora, G., & Katz, R. R. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180012 · Cited by 17
de Maricourt, P., Jay, T. M., GONCALVES, P. S., Löo, H., & Gaillard, R. (2014) · L Encéphale · doi:10.1016/j.encep.2013.09.001 · Cited by 18
Antisuicidal efficacy of ketamine infusion in suicidal patients of depressive disorder
Pathak, U., Ahuja, S. K., Dwivedi, R., Mishra, N., Kumar, P. J., Mishra, D. K., & Singh, R. (2021) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_80_21 · Cited by 19
Li, J., Temizer, R., Chen, Y.-W., & Aoki, C. J. (2024) · Brain Structure and Function · doi:10.1007/s00429-023-02740-w · Cited by 13
Kadriu, B., Deng, Z., Kraus, C., Henter, I. D., Lisanby, S. H., & Zarate, C. A. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19ac13138 · Cited by 15
New trends in pharmacological control of neuropsychiatric symptoms of dementia
Scuteri, D., Corasaniti, M. T., Tonin, P., Nicotera, P., & Bagetta, G. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.09.002 · Cited by 18
Novel uses of ketamine in the emergency department
Corwell, B. N., Motov, S. M., Davis, N. L., & Kim, H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2100883 · Cited by 15
Baptista, P. P. A., Saur, L., Bagatini, P. B., Greggio, S., Venturin, G. T., Vaz, S. P., Ferreira, K., Junqueira, J. S., Lara, D. R., DaCosta, J. C., et al. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1576-3 · Cited by 18
Molecular Mechanism and Clinical Relevance of Ketamine as Rapid‐Acting Antidepressant
Pešić, V., Petrović, J., & Jukić, M. M. (2016) · Drug Development Research · doi:10.1002/ddr.21335 · Cited by 15
Maraone, A., Tarsitani, L., Pinucci, I., & Pasquini, M. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i9.568 · Cited by 19
Wilke, S. A., Lavi, K., Byeon, S., Donohue, K. C., & Sohal, V. S. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.11.008 · Cited by 17
CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
Nguyen, T. M. L., McGowan, J. C., & Gardier, A. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108936 · Cited by 17
Underwood, M. D., Bakalian, M. J., Johnson, V. L., Kassir, S. A., Ellis, S. P., Mann, J. J., & Arango, V. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa009 · Cited by 13
Gonzalez, S., Vasavada, M. M., Njau, S. N., Sahib, A. K., Espinoza, R. T., Narr, K. L., & Leaver, A. M. (2020) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2020.08.006 · Cited by 14
Innovative approaches to treatment - refractory depression: The ketamine story
Rao, T. S., & Andrade, C. (2010) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.64573 · Cited by 14
Tucciarone, J., Bandeira, I. D., Blasey, C. M., Kratter, I. H., Ehrie, J., Keller, J., Pankow, H., Chang, M., Hawkins, J., Evers, A. G., et al. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250840 · Cited by 14
Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine
Evans, V. D., Arenas, A., Shinozuka, K., Tabaac, B. J., Beutler, B. D., Cherian, K. N., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001721 · Cited by 19
Henderson, T. A. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.177708 · Cited by 13
Conceptualizing death: How do suicidal adolescents view the end of their lives?
Tezanos, K. M., Pollak, O. H., & Christine, B. W. (2021) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12774 · Cited by 13
High Yielding Continuous-Flow Synthesis of Norketamine
Veguillas, M., Moore, J. C., Howie, R. A., Castledine, R. A., Bourne, S. L., Jenkins, G. N., Licence, P., Poliakoff, M., & George, M. W. (2022) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00407 · Cited by 13
(Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy
Alario, A. A., & Niciu, M. J. (2022) · Chronic Stress · doi:10.1177/24705470221128017 · Cited by 17
Chaves, T. V., Wilffert, B., & Sanchez, Z. M. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1769118 · Cited by 15
Is there a risk of esketamine misuse in clinical practice?
Roncero, C., Torres, M. M., Szerman, N., Torrens, M., Vega, P., Andrés-Olivera, P., & Alvarez, E. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241310685 · Cited by 16
Clinical trials for rapid changes in suicidal ideation: lessons from ketamine
Ballard, E. D., Fields, J., Farmer, C. A., & Zarate, C. A. (2021) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12663 · Cited by 10
Yao, H., Wang, X., Chi, J., Chen, H., Liu, Y., Jiayi, Y., Yu, J., Ruan, Y., Xiang, X., Pi, J., et al. (2024) · Molecules · doi:10.3390/molecules29050964 · Cited by 11
Major challenges in youth psychopathology: treatment-resistant depression. A narrative review
Menculini, G., Cinesi, G., Scopetta, F., Cardelli, M., Caramanico, G., Balducci, P. M., Giorgi, F. D., Moretti, P., & Tortorella, A. A. V. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1417977 · Cited by 13
Current Trends in Identifying Rapidly Acting Treatments for Depression
Ionescu, D. F., & Papakostas, G. I. (2016) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-016-0075-4 · Cited by 12
Freitas, A. E., Heinrich, I. A., Moura, T. D. M., Fraga, D. B., Costa, A. P., Azevedo, D., Brocardo, P. S., Kaster, M. P., Leal, R. B., & Rodrigues, A. L. S. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113398 · Cited by 11
A Bibliometric Analysis of Research on Ketamine From 2001 to 2020
Miao, H., Yu, K., Gao, D., Lin, X., Cao, Y., Liu, X., Qiao, H., & Li, T. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.839198 · Cited by 12
Guhathakurta, D., Petrušková, A., Akdaş, E. Y., Perelló‐Amorós, B., Frischknecht, R., Anni, D., Weiss, E., Walter, M., & Fejtová, A. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02744-y · Cited by 10
Sohn, M. N., Cole, J., Bray, S., & McGirr, A. (2025) · Psychological Medicine · doi:10.1017/s0033291724003313 · Cited by 11
Cabrera‐Mendoza, B., Martínez‐Magaña, J. J., Mendoza, A. D. G., Sarmiento, E., Ruíz-Ramos, D., Tovilla‐Zárate, C. A., González‐Castro, T. B., Juárez‐Rojop, I. E., la Cruz, D. D. G.-D., López‐Armenta, M., et al. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.01.008 · Cited by 11
Temizer, R., Chen, Y., & Aoki, C. J. (2022) · Synapse · doi:10.1002/syn.22253 · Cited by 10
The Role of Gut Microbiota in the Antidepressant Effects of Ketamine
Wang, Y., Xu, X., Luo, A., & Yang, C. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_8 · Cited by 10
Treatment of suicidal depression with ketamine in rapid cycling bipolar disorder
Sampath, H., Sharma, I. L., & Dutta, S. K. (2016) · Asia-Pacific Psychiatry · doi:10.1111/appy.12220 · Cited by 10
Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders
Gómez de San José, N., Goossens, J., Al Shweiki, M. R., Halbgebauer, S., Oeckl, P., Steinacker, P., Danzer, K. M., Graf, H., Schönfeldt-Lecuona, C., Belbin, O., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.10.010 · Cited by 9
Feng, W., Chen, C., Zeng, Y., & Zhang, B. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111152 · Cited by 10
Ketamine in Clinical Practice: Transitioning from Anesthetic Agent to Psychiatric Therapeutic
Quintero, J.-M., Bustos, R., Lechtig, S., Beltran, S., & Zarate, C. A. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009585330.007 · Cited by 12
Similar destabilization of neural dynamics under different general anesthetics
Eisen, A. J., Bardon, A. G., Ballesteros, J. J., Bastos, A. M., Donoghue, J., Mahnke, M. K., Brincat, S. L., Roy, J. E., Ishizawa, Y., Brown, E. N., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117048 · Cited by 8
Guanosine as a promising target for fast-acting antidepressant responses
Camargo, A., & Rodrigues, A. L. S. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173422 · Cited by 9
Metadata
- Authors
- Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- Harvard University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Price, Rebecca B.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 66
- Issue
- 5
- Pages
- 522-526
- ISSN
- 0006-3223 (ISSN-L)
- PMC
- PMC2935847
- OpenAlex
- W2118815581
- Cited by
- 600
- References
- 22
- Citations by year
- 2026: 15 · 2025: 16 · 2024: 18 · 2023: 25 · 2022: 43 · 2021: 49 · 2020: 43 · 2019: 39 · 2018: 31 · 2017: 34 · 2016: 46 · 2015: 62 · 2014: 45 · 2013: 42 · 2012: 43
- FWCI
- 21.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (F31 MH081468, K23-MH-069656, MO1-RR-00071)
- National Alliance for Research on Schizophrenia and Depression
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- intravenous ketamine, treatment-resistant depression, suicidality, suicide risk, Implicit Association Test, rapid antidepressant effects, suicide assessment
- MeSH terms
- Suicide Prevention, Depression, Drug Resistance, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Suicide, Cohort Studies, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
